Filing Flows › Verrica Pharmaceuticals (VRCA) › Q2 2026
Verrica Pharmaceuticals (VRCA) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 6, 2026
Verrica Pharmaceuticals (VRCA) reported revenue of $5.9M for the second quarter 2026 (Q2 2026), -54% from a year earlier and +17% from the quarter before. Operating margin was -223.4%, net loss $13.2M (224.4% of revenue).
Verrica Pharmaceuticals, Q2 2026: revenue $5.9M (-54% year over year), operating margin -223.4%, net loss $13.2M, operating cash flow −$9.3M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $5.9M | +17% | -54% |
| Operating profit | −$13.1M | — | -967% |
| Net earnings | −$13.2M | — | -6548% |
| Operating cash flow | −$9.3M | — | — |
What changed
Revenue was $5.9M in Q2 2026, down 54% year over year and up 17% from the previous quarter.
Operating costs exceeded revenue by $13.1M, an operating margin of -223.4%. Total costs grew 69% against a revenue fall of 54%. The fastest-growing cost line was Other operating costs (+421%). The quarter ended with a net loss of $13.2M, wider than the previous quarter's $9.7M loss.
Operating cash flow was −$9.3M. Non-cash charges added back $15K of depreciation and $1.2M of share-based compensation. Working capital and other items added $2.6M.
Questions
What was Verrica Pharmaceuticals' revenue in the second quarter 2026?
Verrica Pharmaceuticals (VRCA) reported revenue of $5.9M for the second quarter 2026 (Q2 2026), -54% from a year earlier and +17% from the quarter before.
Was Verrica Pharmaceuticals profitable in the second quarter 2026?
Operating loss was $13.1M (-223.4% of revenue) and net loss $13.2M.